etirinotecan pegol

11/01/2015 - "This trial did not demonstrate an improvement in overall survival for etirinotecan pegol compared to treatment of physician's choice in patients with heavily pre-treated advanced breast cancer. "
11/01/2015 - "We assessed whether etirinotecan pegol is superior to currently available treatments for patients with previously treated, locally recurrent or metastatic breast cancer. "
01/01/2017 - "Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial."
01/01/2016 - "Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial."
11/01/2013 - "On the basis of the overall clinical data, pharmacokinetics, and tolerability profile, etirinotecan pegol 145 mg/m(2) every 21 days has been selected for a phase 3 trial against treatment of physician's choice in patients with advanced breast cancer."

01/01/2013 - "A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors."
01/01/2018 - "Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors."
12/01/2014 - "The increased tumor exposure following etirinotecan pegol correlated with strong and prolonged suppression of tumor growth. "
12/01/2014 - "Etirinotecan pegol was active in all tumor models. "
12/01/2014 - "Etirinotecan pegol was administered intravenously (once or every 3-7 days) to animals with established tumors. "

07/01/2019 - "ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases."
11/01/2022 - "Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases."
11/01/2022 - "Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases-Reply."
01/01/2022 - "Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial."
07/01/2019 - "The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. "

11/10/2013 - "Both schedules of etirinotecan pegol showed activity in patients with heavily pretreated ovarian cancer, with encouraging ORR and PFS rates. "
08/01/2019 - "Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer."
11/01/2017 - "A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer."
11/01/2017 - "Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). "
11/10/2013 - "These findings provide support to directly compare etirinotecan pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistant ovarian cancer."

01/01/2016 - "In the phase II advanced breast cancer setting, etirinotecan pegol provided promising activity, which was maintained in poor prognostic subgroups, with low rates of neutropenia and neuropathy - issues plaguing our currently available agents. "
01/01/2017 - "Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration."
01/01/2017 - "The relationship between incidences of neutropenia and 10-hydroxy-7-ethyl camptothecin (SN38) exposure was explored using SN38 pharmacokinetic and neutrophil count data from toxicology studies of etirinotecan pegol (EP) and irinotecan in beagle dogs. "